Researchers at Institute of Microbiology and Epidemiology target vaccines
2008 JAN 13 -- Researchers detail in 'Protection against lethal subcutaneous challenge of virulent Y. pestis strain 141 using an F1-V subunit vaccine,' new data in vaccines. "In this study, we designed and engineered a two-component recombinant fusion protein antigen as a vaccine candidate against the possible biological threat of Yersinia pestis. The recombinant F1-V protein was formulated with Alhydrogel," researchers in Beijing, People's Republic of China report. "A four-time injection with a dosage of 10, 20 and 50 microg/mouse in about two months was adopted for vaccination. Serum antibodies and subclass of T helper cells were measured and analyzed. After the final vaccination, the mice were challenged by 141 strain with 25-600 LD(50)," wrote D. Wang and colleagues, Institute of Microbiology and Epidemiology. The researchers concluded: "The recombinant vaccine was capable of inducing protective immunity against subcutaneous challenge. The level of serum IgG was supposed to be a main factor that affected the final protection of challenge. 20 microg recombinant protein could induce an endpoint titer of serum IgG as high as 51200, which was enough to afford 100% protection against 400 LD(50) virulent 141 challenge. The antibody isotype analysis showed that the vaccine induced predominantly an IgG1 rather than IgG2a response. Flow cytometric analysis revealed that Alhydrogel significantly helped induce a stronger humoral immunity instead of CTL cellular response. These findings suggested that the plague F1-V subunit vaccine is promising for the next plague vaccine." Wang and colleagues published their study in Science In China Series C, Life Sciences (Protection against lethal subcutaneous challenge of virulent Y. pestis strain 141 using an F1-V subunit vaccine. Science In China Series C, Life Sciences, 2007;50(5):600-4). For additional information, contact D. Wang, Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China. Publisher contact information for the journal Science In China Series C, Life Sciences is: Science China Press, 16 Donghuangchenggen North St., Beijing 100717, People's Republic of China. Keywords: People's Republic of China, Beijing, Bacteriology, Biotechnology, Bubonic Plague, Drug Development, Epidemiology, Microbiology, Proteomics. Fusion Proteins, Therapy, Treatment, Vaccines, Yersinia Pestis. This article was prepared by Medical Letter on the CDC & FDA editors from staff and other reports. Copyright 2008, Medical Letter on the CDC & FDA via NewsRx.com.
|
